Loading...
XKRX003060
Market cap94mUSD
Jan 09, Last price  
700.00KRW
1D
1.45%
1Q
-22.99%
Jan 2017
-96.49%
Name

Aprogen Biologics Inc

Chart & Performance

D1W1MN
XKRX:003060 chart
P/E
P/S
1.58
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
-11.27%
Rev. gr., 5y
13.99%
Revenues
87.36b
+34.01%
17,117,086,00021,137,045,00062,227,816,00016,689,083,00050,122,955,34033,769,678,25029,543,262,23033,092,222,03040,324,275,48044,122,492,68046,100,951,70045,395,389,40050,903,820,55053,319,976,20056,481,701,59065,190,359,33087,363,627,712
Net income
-118.27b
L
-10,496,595,000-5,489,801,000-8,097,501,000-704,422,000-4,560,115,000-24,870,962,000-20,852,021,000-3,887,364,7402,760,674,900-3,917,714,760-16,364,749,000-1,215,412,540-3,466,524,12018,917,569,9608,102,570,3705,583,620,100-118,269,720,510
CFO
-33.65b
L
-4,773,709,000-3,461,909,000-4,994,895,000247,922,000-3,895,277,730-1,649,487,870-1,701,829,640-6,917,181,5701,847,053,050449,980,360-8,927,787,2801,331,380,770713,734,0208,088,157,750-6,226,540,19025,728,188,300-33,650,775,380
Earnings
Mar 12, 2025

Profile

Aprogen pharmaceuticals,Inc. manufactures and sells pharmaceutical products primarily in South Korea. It offers approximately 200 types of medicines, including ethical and over the counter drugs. The company offers its drugs for transfusion, digestive system, osteoarthritis, skeletal muscle relaxants, NSAIDs, osteoporosis, circulatory system, endocrine, respiratory system, urinary system, depilatory, antihistamines and antiallergics, obesity, brain function, neurologics, and male pattern hair loss. It also provides anti-biotic, anti-fungal, anti-viral, anti-ulcerant, anti-epliepsy products; external agents; anti-cancer drugs; amino-acid nutrient transfusion agents; and cosmetics. The company was formerly known as Schnell Biopharmaceuticals, Inc. and changed its name to Aprogen pharmaceuticals,Inc. in April 2017. Aprogen pharmaceuticals,Inc. was founded in 1960 and is headquartered in Seongnam, South Korea.
IPO date
Oct 19, 1984
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
87,363,628
34.01%
65,190,359
15.42%
Cost of revenue
132,962,765
57,926,980
Unusual Expense (Income)
NOPBT
(45,599,137)
7,263,379
NOPBT Margin
11.14%
Operating Taxes
1,947,066
1,260,151
Tax Rate
17.35%
NOPAT
(47,546,203)
6,003,228
Net income
(118,269,721)
-2,218.15%
5,583,620
-31.09%
Dividends
Dividend yield
Proceeds from repurchase of equity
35,574,520
244
BB yield
-19.39%
0.00%
Debt
Debt current
130,720,460
134,608,901
Long-term debt
69,913,837
603,620
Deferred revenue
Other long-term liabilities
9,558,467
9,386,470
Net debt
52,934,337
53,810,668
Cash flow
Cash from operating activities
(33,650,775)
25,728,188
CAPEX
(28,087,917)
(1,545,199)
Cash from investing activities
(95,205,708)
(53,000,826)
Cash from financing activities
115,289,354
15,782,353
FCF
25,056,526
(192,499,302)
Balance
Cash
10,053,360
99,073,617
Long term investments
137,646,600
(17,671,765)
Excess cash
143,331,779
78,142,334
Stockholders' equity
(180,413,847)
366,504,224
Invested Capital
739,661,086
568,351,578
ROIC
1.13%
ROCE
1.12%
EV
Common stock shares outstanding
83,225
53,652
Price
2,203.96
-42.35%
3,822.73
-44.42%
Market cap
183,424,057
-10.57%
205,096,227
-44.06%
EV
236,358,395
339,561,644
EBITDA
(24,201,534)
9,667,364
EV/EBITDA
35.12
Interest
3,668,234
274,408
Interest/NOPBT
3.78%